NR1I2 and hepatocellular carcinoma: The HCC cells may be resistant to molecular targeted drugs through a variety of mechanisms: (1) compensation between different signaling pathways (77–79); (2) epithelial–mesenchymal transition (80–82); (3) cancer stem cells (83–85); (4) PXR and other drug metabolism clearance mechanism (63); and (5) Notch pathway and other cell prosurvival and antiapoptotic mechanisms (38, 86–88).